Interferon beta-1a: all 82 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Early Interferon-beta Treatment for West-Nile Virus InfectionRecruitingNCT06510426Phase 2
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral InfectionTerminatedNCT06999603Phase 2Results posted
• Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19TerminatedNCT04860518Phase 2Results posted
• Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19CompletedNCT04732949Phase 3Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedNCT04492475Phase 3Results posted
• Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A ProductsCompletedNCT04183491Phase 1Results posted
• Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAATerminatedNCT03119701Phase 2Results posted
• Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple SclerosisCompletedNCT02727907Phase 2/3Results posted
• Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)TerminatedNCT02622724Phase 3Results posted
• Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™CompletedNCT02254304Phase 4Results posted
• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateTerminatedNCT02117050Phase 4Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy VolunteersCompletedNCT01766024Phase 1Results posted
• Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
• Assessing Tolerability of Avonex Intramuscular InjectionsCompletedNCT01641120Not applicableResults posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialCompletedNCT01085318Phase 4Results posted
• A Pilot Trial of Interferon Beta-1a in Alzheimer's DiseaseCompletedNCT01075763Phase 2Results posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis SubjectsCompletedNCT00828204Phase 3Results posted
• Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)CompletedNCT00813709Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsTerminatedNCT00784836Phase 3Results posted
• A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative ColitisCompletedNCT00616434Phase 2Results posted
• REbif FLEXible Dosing in Early Multiple Sclerosis (MS)CompletedNCT00404352Phase 3Results posted
• Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisCompletedNCT00367484Phase 4Results posted
• A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated SyndromeCompletedNCT00287079Phase 3Results posted
• Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple SclerosisCompletedNCT00246324Phase 4Results posted
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedNCT00211887Phase 3Results posted
• Long Term Study of Avonex Therapy Following a First Attack of Multiple SclerosisCompletedNCT00179478Phase 4Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• Interferon-beta1a (AVONEX) Treatment of Ulcerative ColitisCompletedNCT00048347Phase 2Results posted
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2
• Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple SclerosisCompletedNCT05242133Phase 3
• Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNCT05024006Not applicable
• World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 TreatmentsStatus unknownNCT04647669Phase 3
• the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19Status unknownNCT04521400Phase 2
• Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) InfectionCompletedNCT04385095Phase 2
• Interferon Beta 1a in Hospitalized COVID-19 PatientsStatus unknownNCT04350671Phase 4
• An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialCompletedNCT04343768Phase 2
• Trial of Treatments for COVID-19 in Hospitalized AdultsCompletedNCT04315948Phase 3
• Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)CompletedNCT03614715Phase 1
• A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or InfluenzaCompletedNCT03570359Phase 2
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
• Phase I BP Interferon (IFN) Beta-001CompletedNCT02515695Phase 1
• Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple SclerosisStatus unknownNCT02364986Phase 1
• Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy VolunteersCompletedNCT02269930Phase 1
• Avonex®: Safety, Blood Levels and EffectsCompletedNCT01863069Phase 1
• Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy VolunteersCompletedNCT01500408Phase 1
• A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsCompletedNCT01416207Phase 1
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)CompletedNCT01181115Phase 3
• Comparing Efficacy and Safety of Inhaled SNG001 to PlaceboCompletedNCT01126177Phase 2
• A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy VolunteersCompletedNCT01119677Phase 1
• Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy SubjectsCompletedNCT01074593Phase 1
• Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex SyringeCompletedNCT00915577Phase 3
• Open-Label Safety Extension Study of AvonexCompletedNCT00915460Phase 4
• Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy VolunteersCompletedNCT00913666Phase 4
• A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy VolunteersCompletedNCT00913250Phase 1
• Immunogenicity and Safety Study of Serum-Free AvonexCompletedNCT00912860Phase 2
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
• Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta TherapyCompletedNCT00493077Phase 4
• Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
• Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's DiseaseTerminatedNCT00304252Phase 2
• Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative ColitisCompletedNCT00303381Phase 2
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
• A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian SubjectsCompletedNCT00249860Phase 3
• A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple SclerosisStatus unknownNCT00217295Phase 2
• Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
• Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS PatientsStatus unknownNCT00151801Phase 2
• EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple SclerosisCompletedNCT00146068Phase 4
• EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisCompletedNCT00137176Not applicable
• Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4
• Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 2
• Safety Study of Interferon Beta 1a to for Acute StrokeCompletedNCT00097318Phase 1

← Interferon beta-1a overview